According to an article in Fierce Biotech, Pfizer's new research chief, Mikael Dolsten proclaimed at the Morgan Stanley Global Healthcare Conference in New York that its pipeline is bulking up with new home grown products just busting to get out.
These include new drugs for arthritis, Alzheimer's disease and stroke prevention. Dolsten said the company is also turning more to biotech (as the Wyeth acquisition no doubt indicates) for external partnerships and these will also extend to research institutions.
See the Reuters story for more.
Posted by Bruce Lehr September 14th 2010.